Camber Announces Launch of Mycophenolate Mofetil Tablets, USP

Key Takeaways

Camber expands its immunosuppressant portfolio with Mycophenolate Mofetil Tablets, USP, following the launch of capsules in April 2025.
The tablets are indicated for preventing organ rejection in kidney, heart, or liver transplant recipients aged three months and older.
Available in 500 mg strength, the tablets are packaged in bottles of 100 and 500, supporting long-term organ acceptance.
Over 48,000 organ transplants occur annually in the U.S., with more than 100,000 patients on waiting lists, highlighting the need for such therapies.

Camber announces the launch of Mycophenolate Mofetil Tablets, USP (generic for CellCept^®), further expanding its immunosuppressant portfolio following the April 2025 launch of Mycophenolate Mofetil Capsules. With over 48,000 organ transplants performed annually in the U.S.—and more than 100,000 patients still on waiting lists—Camber remains committed to providing critical therapies that support long-term organ acceptance and improve transplant outcomes.

Mycophenolate Mofetil Tablets, USP are an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

Mycophenolate Mofetil Tablets, USP are available in 500 mg strength, packaged in bottles of 100 and 500 tablets.

To find out more information on Mycophenolate Mofetil Tablets, USP, please visit: www.camberpharma.com/mycophenolatetablets

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!